Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
BioHealthonomics Inc. is a research and development biotechnology & healthcare com...
BioHealthonomics Inc. is a research and develop...
Soliton, Inc. is a medical device company with a novel and proprietary platform te...
Soliton, Inc. is a medical device company with ...
Grifols is a global healthcare company founded in Barcelona in 1909 committed to i...
Grifols is a global healthcare company founded ...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...
Founded on September 28, 2005 through the merge...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Join the National Investor Network and get the latest information with your interests in mind.